The latest price target for Voyager Therapeutics (NASDAQ:VYGR) was reported by Canaccord Genuity on March 13, 2025. The analyst firm set a price target for $12.00 expecting VYGR to rise to within 12 months (a possible 219.80% upside). 20 analyst firms have reported ratings in the last year.

The latest analyst rating for Voyager Therapeutics (NASDAQ:VYGR) was provided by Canaccord Genuity, and Voyager Therapeutics maintained their buy rating.

The last upgrade for Voyager Therapeutics Inc happened on January 2, 2024 when Wells Fargo raised their price target to $14. Wells Fargo previously had an equal-weight for Voyager Therapeutics Inc.

There is no last downgrade for Voyager Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Voyager Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Voyager Therapeutics was filed on March 13, 2025 so you should expect the next rating to be made available sometime around March 13, 2026.

While ratings are subjective and will change, the latest Voyager Therapeutics (VYGR) rating was a maintained with a price target of $14.00 to $12.00. The current price Voyager Therapeutics (VYGR) is trading at is $3.75, which is out of the analyst’s predicted range.